Archives
-
Dual SMAD/Wnt Inhibition for iPSC-RGCs
2026-09-11
The reference study presents a chemically defined, non-genetic method for directing induced pluripotent stem cells toward retinal ganglion cells through coordinated SMAD and canonical Wnt inhibition. Its reproducibility, high RGC yield, and subsequent Thy-1 enrichment provide a useful framework for glaucoma modeling and comparative studies of retinal neurodegeneration.
-
RG7388 Workflow for p53-Driven Cancer Assays
2026-09-11
RG7388 enables a practical, multi-level workflow for testing selective MDM2 blockade, from HTRF target engagement to p53-dependent apoptosis and combination treatment studies. This guide connects product performance data with the MDM1–p53 chemoradiotherapy findings reported in colorectal cancer while clearly separating established evidence from assay-development recommendations.
-
CCCP: A Perturbation Lens on Mitochondrial Morphology
2026-09-10
CCCP (carbonyl cyanide m-chlorophenyl hydrazine) is more than an oxidative phosphorylation inhibitor: it can serve as a controlled perturbation for interpreting mitochondrial morphology. This article connects CCCP-based bioenergetic stress testing with deep-learning analysis of urine-derived stem cells while defining the limits of translational inference.
-
Novobiocin: Mechanism, Evidence, and Workflows
2026-09-10
Novobiocin is an aminocoumarin antibiotic that inhibits bacterial DNA gyrase subunit B and can also bind the C-terminal nucleotide-binding site of Hsp90. This article separates product-reported activity ranges from validated experimental conclusions and provides source-linked workflow parameters for antibacterial, antiparasitic, antiviral, and resistance research.
-
WNT5a/GSK3/β-Catenin Controls FAP Adipogenesis
2026-09-09
The reference study identifies the WNT5a/GSK3/β-catenin axis as a key regulator of adipogenic differentiation in skeletal muscle fibro/adipogenic progenitors. By combining pharmacological inhibition, mass cytometry, animal models, network modeling, and transcriptomic datasets, it links impaired WNT5a signaling to pathological fat accumulation and reduced muscle-supportive activity.
-
Paroxetine Mesylate: From Target to Phenotype
2026-09-09
Paroxetine Mesylate is more than a Selective serotonin reuptake inhibitor: its SERT, CYP2D6, MET, and ERBB3 activities create a demanding model for translational assay design. This article explains how to separate direct target engagement from downstream anticancer phenotypes and convert the evidence into rigorous research decisions.
-
Dual Enzyme-Responsive Peptide Selectivity
2026-09-08
Kim and colleagues developed a zwitterionic peptide amphiphile that uses sequential MMP-7-mediated disassembly and cathepsin B-directed assembly to form fibers inside cancer-cell lysosomes. The design produced a reported cancer selectivity index of 64.1 and tumor regression in an HT-29 xenograft model, while highlighting the dependence of this strategy on enzyme distribution and model context.
-
Prostaglandin E2 for Reliable Cell Assays
2026-09-08
A scenario-based guide to using Prostaglandin E2 (SKU B7005) in viability, proliferation, cytotoxicity, organoid, and inflammation workflows. It connects receptor pharmacology with solvent control, protocol optimization, data interpretation, and practical supplier selection.
-
AmpC/AmpD Mutations Drive C/T Resistance
2026-09-07
Deroche and colleagues combined isogenic Pseudomonas aeruginosa mutants, sequential time-kill experiments, and semi-mechanistic PKPD modeling to separate immediate and adaptive effects of ampC and ampD mutations on ceftolozane-tazobactam activity. The work shows that the combined AmpC G183D and AmpD H157Y genotype produces a stronger and time-dependent resistance phenotype while also influencing imipenem susceptibility.
-
Ibotenic acid: Workflows for Neurotoxicity Studies
2026-09-07
Build time-resolved glutamatergic experiments with Ibotenic acid, pairing behavioral observations with biochemical, c-fos, and Nissl readouts. This guide distinguishes acute receptor activation from tissue injury and translates recent murine toxicity findings into practical assay and troubleshooting choices.
-
Forsythoside E: PKM2 Workflow Guide
2026-09-05
Forsythoside E connects PKM2 tetramerization, macrophage metabolism, and inflammatory signaling in a practical workflow for immunometabolism studies. This guide combines cell, protein-binding, and in vivo design with assay-specific troubleshooting for sepsis-induced liver injury research.
-
Dibutyryl-cAMP, Sodium Salt: Practical Workflow
2026-09-04
Build reproducible cAMP signaling experiments with a cell-permeable analog that supports PKA activation, inflammation modulation, and neuronal pathway studies. This workflow pairs dose-ranging, time-course controls, and brain-slice assay design with practical troubleshooting for DBcAMP sodium salt.
-
Cy3 Goat Anti-Rabbit IgG (H+L) Antibody Guide
2026-09-04
Cy3 Goat Anti-Rabbit IgG (H+L) Antibody provides fluorescent detection of rabbit primary antibodies in immunofluorescence, immunohistochemistry, immunocytochemistry, and flow cytometry workflows. It is a research-use reagent only; no directly matched paper evidence or assay-specific working dilution was provided, so performance should be established with appropriate controls and titration.
-
rhBNP, Selenium Recycling, and Renal Ferroptosis
2026-09-03
The reference study identifies selenocysteine lyase 1 (SCLY)-dependent selenium recycling as a mechanistic basis for recombinant human brain natriuretic peptide (rhBNP) protection against renal ischemia-reperfusion injury. By integrating clinical analysis, rat models, transcriptomics, and HK2 cell experiments, the work links rhBNP signaling to suppression of ferroptosis and apoptosis, while highlighting SCLY as a potential therapeutic target in acute kidney injury.
-
O6-Benzylguanine for MGMT Inhibition Research
2026-09-03
O6-Benzylguanine provides a direct pharmacological route to MGMT inhibition, helping researchers separate DNA repair activity from transcriptional regulation in alkylator-resistance models. This article presents an assay-ready workflow for testing sensitization to alkylating agents, validating DNA damage, and interpreting results alongside AP-2α–MGMT biology.